tbuckley/cabot-search huggingface dataset:
A NOVEL ECHOCARDIOGRAPHIC INDEX OF RELATIVE VALVE LOAD PREDICTS CLINICAL OUTCOMES IN PATIENTS WITH MEDICALLY-MANAGED SEVERE AORTIC STENOSIS
Authors: Nicholas Ngiam, Nicholas Chew, Ching-Hui Sia, Hui Wen Sim, Benjamin Yong-Qiang Tan, William Kong, Tiong-Cheng Yeo, Kian Keong Poh
Journal: Journal of the American College of Cardiology (2020)
EARLY AND MID-TERM OUTCOMES OF FEMORO-ILIO-CAVAL VEIN STENT IMPLANTATION
Authors: Robert Sogomonian, Carlos Andres Gonzalez-Lengua, Mikko A. Tesalona, Pouya Mohajer, Balaram Krishna Hanumanthu, Kevin Liu, Nima Taghipour, Ramesh Gowda, Deepika Misra
Journal: Journal of the American College of Cardiology (2020)
LONG-TERM OUTCOMES OF TRANSCATHETER MITRAL VALVE REPLACEMENT USING A BALLOON EXPANDABLE VALVE
Authors: Marvin H. Eng, Faraj Kargoli, Tiberio M. Frisoli, Dee Dee Wang, James Chihong Lee, Pedro Villablanca, Mayra Guerrero, Adam Greenbaum, Chak-Yu So, Guson Kang, Janet Fredal Wyman, William W. O'Neill
Journal: Journal of the American College of Cardiology (2020)
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic
Authors: Elissa Driggin, Mahesh V. Madhavan, Behnood Bikdeli, Taylor Chuich, Justin Laracy, Giuseppe Biondi-Zoccai, Tyler S. Brown, Caroline Der Nigoghossian, David A. Zidar, Jennifer Haythe, Daniel Brodie, Joshua A. Beckman, Ajay J. Kirtane, Gregg W. Stone, Harlan M. Krumholz, Sahil A. Parikh
Journal: Journal of the American College of Cardiology (2020)
Utility of standardized letters in assisting primary care providers (PCPs) with the care of cancer survivors (CS).
Authors: Ali Moghaddamjou, Caroline Speers, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2013)

9593 Background: Survivorship care plans have strong face validity, but individualizing plans to each patient’s needs can be resource intensive. At our institution, a 1-page standardized letter that outlines the essential components of follow-up care is mailed to PCPs at the time of a patient’s discharge. This letter highlights the recommended frequency and interval of tests and physician visits. Our study aims were to 1) characterize PCPs’ attitudes regarding these letters and 2) identify potential strategies to improve this channel of communication with PCPs. Methods: Self-administered surveys were mailed to high-volume PCPs in British Columbia, defined as those whose practices followed &gt;/=5 breast or colorectal CS in the preceding year. The survey asked about practice characteristics and PCPs’ views towards the content and format of these standardized letters. Logistic regression models were constructed to delineate factors associated with follow-up preferences. Results: Among 787 PCPs, 507 (64%) responded: median year since graduation was 27 (range 1-62), 67% were men, 38% had a faculty appointment, 71% practiced in a group, and 92% were paid fee-for-service. When asked about their perspectives regarding the care of CS, 388 (77%) indicated they were comfortable providing follow-up with 299 (74%) reporting that the standardized letter contained adequate information. In regression models, PCPs who were comfortable with cancer surveillance and those who graduated greater than 30 years ago were more likely to view the standardized letter as useful (OR 2.50, 95% CI 1.41-4.43 and OR 2.31, 95% CI 1.24-4.33, respectively) and important (OR 4.07, 95% CI 1.80-9.19 and OR 3.14, 95% CI 1.01-9.74, respectively). Among 103 (26%) PCPs who found the letter to be insufficient, most wanted additional details about the cancer diagnosis (88%), specific information on the toxicities of therapy (88%), and the estimated risk of recurrence (84%). Conclusions: Most PCPS were satisfied with a simple, standardized letter that outlines the necessary components of cancer follow-up. PCPs with less familiarity with cancer surveillance may be a target group that benefits most from individualized survivorship care plans.
PRIMARY VERSUS NON-PRIMARY PCI AMONG STEMI PATIENTS IN INDIA: A RETROSPECTIVE ANALYSIS OF THE ACUTE CORONARY SYNDROME QUALITY IMPROVEMENT IN KERALA (ACS QUIK) CLUSTER-RANDOMIZED STEPPED WEDGE TRIAL
Authors: Mazen Saadi Albaghdadi, Haitham Khraishah, Mark Siedner, Ahmed ElGuindy, Nino Mihatov, Khuzeima Khanbhai, Pedro Pallangyo, Amisha Patel, Abigail Baldridge, Mohamed Janabi, Kevin Kennedy
Journal: Journal of the American College of Cardiology (2020)
Definition of a high-risk population among patients with AL amyloidosis not undergoing autologous stem cell transplantation using bone marrow plasmacytosis and the presence of CRAB.
Authors: Taxiarchis Kourelis, Morie Gertz, Martha Lacy, Francis Buadi, Suzanne R. Hayman, Shaji Kumar, Steven R. Zeldenrust, Nelson Leung, Robert A. Kyle, Stephen Russell, David Dingli, John Anthony Lust, Yi Lin, Prashant Kapoor, Vincent Rajkumar, Angela Dispenzieri
Journal: Journal of Clinical Oncology (2013)

8516 Background: There is consensus that light chain amyloidosis (AL) patients with CRAB criteria (abnormal calcium or renal function, anemia or lytic bone lesions) also have multiple myeloma (MM). These patients are typically excluded from AL trials; however, AL patients with &gt;= 10% bone marrow plasma cells (BMPC) in the absence of CRAB are included in trials along with AL with &lt; 10% BMPC. We postulated that the currently used dichotomy may be incorrect and examined the spectrum of AL with and without MM. Methods: We identified 1,272 patients with AL seen within 90 days of diagnosis, between January 1, 2000, and December 31, 2010. We defined the population of patients with coexisting MM based on the existence of CRAB (AL-CRAB-MM). Patients without CRAB were divided into two groups, AL-only (&lt;10% BMPC) and AL-PC-MM (&gt;=10% BMPC). Results: Among the 1,272 patients, 117 (9%) had AL-CRAB-MM, 476 (37%) had AL-PC-MM, and 679 (53%) had AL only. Their respective median overall survivals (OS) were 16.2, 15.8, and 28.4 months (p&lt;0.0001). Autologous stem cell transplant (ASCT) was performed in 203 (30%), 138 (29%) and 23 (20%) patients respectively. Since the outcomes of AL-CRAB-MM and AL-PC-MM were similar, they were pooled for univariate and multivariate analyses. On multivariate analysis, AL-CRAB-MM and AL-PC-MM retained negative prognostic value independent of age, cardiac stage, prior autologous stem cell transplant (ASCT), beta 2 microglobulin, and dFLC. We next considered whether patients received ASCT as part of their treatment. For those patients who never received ASCT, the 5-year OS were 19%, 14%, and 31%, p&lt;0.001, for AL-CRAB-MM, AL-PC-MM, and AL only respectively. In contrast, for those patients who received ASCT, the respective 5-year OS were 46%, 56%, and 73%, p&lt;0.001. Conclusions: AL patients with &gt;=10% BMPCs have a poor prognosis similar to patients with AL-CRAB-MM and should therefore be considered as AL with MM.
IMPACT OF DAPAGLIFLOZIN ON LEFT VENTRICULAR DIASTOLIC FUNCTION IN DIABETIC PATIENTS WITH HEART FAILURE COMPLICATING CARDIOVASCULAR RISK FACTORS
Authors: Fumitaka Soga, Hidekazu Tanaka, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2020)
COMPARISON OF IN-HOSPITAL OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION BETWEEN HEART TRANSPLANT RECIPIENTS AND NON-TRANSPLANT PATIENTS
Authors: Sakiru Isa, Olajide Buhari, Hafiz Khan, Muminat Yetunde Adeniran-Isa, Mahin Khan, Ebrahim Abdelrazzak, Hameem Changezi
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC ROLE OF COMORBIDITIES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Authors: Fabio Dardi, Massimiliano Palazzini, Riccardo Bertozzi, Elisa Zuffa, Daniele Guarino, Alessandro De Lorenzis, Filippo Pasca, Ilenia Magnani, Mariangela Rotunno, Alberto Ballerini, Alessandra Manes, Nazzareno Galié
Journal: Journal of the American College of Cardiology (2020)
Utility of nonsurgical diagnostic specimens in cellular differentiation and molecular profiling (EGFR mutation and EML4-ALK detection) of NSCLC.
Authors: Victor Cohen, Amanda Levitt, Goulnar Kasymjanova, Jason Scott Agulnik, Amr Al Banna, David I. Small, Carmela Pepe, Alan Spatz, Guilherme Brandao
Journal: Journal of Clinical Oncology (2012)

e18061 Background: The utility of different non-surgical specimens for the accurate determination of cellular and molecular attributes in NSCLC has yet to be established. The primary objective of this study was to determine and compare the yield of non-surgical specimens for the accurate cellular differentiation of NSCLC and analysis of EGFR and EML4-ALK mutations. Methods: Patients with a histologic diagnosis of NSCLC from January 2004 to September 2010 were included. Diagnosis was based on cytological characteristics and IHC analysis. Fragment analysis and real-time PCR methods were used for EGFR mutation detection. EML4-ALK rearrangements were detected by FISH. Diagnostic specimens were divided into pathology specimens (PS) and cytology specimens (CS). PS included surgical and non-surgical biopsies. CS included FNA (TBNA and TTNA) and body fluid samples. These groups were compared using χ2 analyses. Yield of histologic analysis was compared in a subgroup of patients who underwent both surgical and non-surgical procedures. Results: 715 patients were included in the study. The yield of CS when compared to PS was lower for cellular differentiation (76% vs. 91%, p &lt;0.0001) and IHC (70% vs. 89%, p &lt;0.0001). Among the CS, TTNA provided better yield than TBNA for cellular differentiation (89% vs. 67%, p &lt; 0.0001) and IHC (85% vs. 72%, p = 0.023). 94 patients underwent both surgical and non-surgical procedures. As compared to surgical biopsies, the yield of non-surgical procedures for cellular classification was 81% in body fluid samples, 68% in FNA, and 88% in non-surgical biopsies. 320 patients were tested for both EGFR and EML4-ALK mutations. The yield of CS versus PS was lower for EGFR mutation status (74% vs. 93% p &lt; 0.0001). Among the CS, TTNA provided better yield than TBNA for EGFR mutation analysis (90% vs. 70%, p = 0.045) and body fluid samples were least likely (59%) to provide EGFR mutation status. Three EML4-ALK FISH-positive cases were identified. All samples were PS. All EML4-ALK positive cases tested negative for EGFR mutations. Conclusions: Non-surgical lung biopsy specimens can yield sufficient samples for histologic assignment and mutational analysis.
DEEP SEDATION IN PATIENTS UNDERGOING PERCUTANEOUS MITRAL VALVE REPAIR USING THE PASCAL ® SYSTEM: FIRST CLINICAL EXPERIENCE
Authors: Tobias Geisler, Rezo Jorbenadze, Elli Tavlaki, Miriam Arikan, Meinrad Gawaz, Juergen Schreieck
Journal: Journal of the American College of Cardiology (2020)
Stanley Cohen: awarded Nobel prize in medicine for his discoveries of growth factors
Authors: Bob Roehr
Journal: BMJ (2020)

Credit: Mark Humphrey/AP/Shutterstock

Newborn mice open their eyes in 12-14 days, but by injecting them with ground up salivary glands Stanley Cohen could get them to open earlier. “Every time I doubled the dose the length of time went down; I got them to open up as early as seven days.” Those experiments led him to identify epidermal growth factor, one of the foundational signalling molecules of biology, and to receiving the 1986 Nobel prize in medicine. His life was an unlikely journey, driven by hard work, good luck, and, above all, insatiable curiosity.

Cohen’s family story mirrored that of countless other Jewish immigrants to New York City in the early 20th century, who saw public education as a way to improve their lot. He excelled in high school and, because it was free, attended city run Brooklyn College during the Depression, graduating in 1943. A childhood bout of polio left him with a pronounced limp, which never slowed him down. It did, however, keep him from being drafted during the second world war.

“Biologists were never going to get anywhere by describing what a cell looks like—you have to know the chemistry to explain the biology,” Cohen told this reporter in an extended …
Pharmacological inhibition and silencing of classical IKK-NF-κB pathway by siRNA sensitizes cancer cells to doxorubicin
Authors: M. Tapia, M. Bosch, M. Rolfe, J. S. Ross, P. Gascón, R. Perona, A. Rovira, J. Albanell
Journal: Journal of Clinical Oncology (2006)

2059 Background: The IKK/NF-κB pathway (IKK1, IKK2 and NEMO; p65, p50, p52, c-Rel, RelB) is involved in chemoresistance. NF-κB is activable by either a classical or an alternative Ipathway. Here we studied whether NF-κB inhibitors sensitized cells to doxorubicin (dox), and assessed the role of individual IKK or NF-κB subunits by RNA interference [ small interfering RNA (siRNA)] on doxorubicin sensitization. Methods: We used BT474 and MDA-MB453 cells (breast) and HeLa cells (cervix). NF-κB inhibitors were bortezomib (Velcade, a proteasome inhibitor, which inhibits NF-κB by promoting accumulation of the inhibitory Iκ B-α) and a NEMO-Binding-Peptide (NBP, which prevents IKK proteins from complexing). NF-κB DNA binding activity was measured by EMSA. Western blot was used to assess nuclear translocation of individual NF-κB subunits (Iκ B-α, p65, c-Rel, RelB, p50 and p52). BT474 and MDA-MB453 cells were cultured with dox with/without NF-κB inhibitors and viability was assayed by MTT. siRNA was used to transiently down-regulate subunits that act preferentially on the classical NF-κ B (p65, p52, c-Rel, or NEMO) or on the alternative pathway (RelB) in HeLa cells. Chemosensitivity of transfected and control cells to dox was measured by MTT. Results: Dox increased NF-κB activity in BT474 and HeLa cells, as assayed by EMSA and/or by showing Iκ B-α degradation and phosphorylation of p65. Pretreatment of BT474 cells with bortezomib followed by dox resulted in a 30% reduction in cell viability compared to dox alone. Moreover, a 40% higher dox sensitivity was observed when cells were pretreated with a NEMO-Binding-Peptide. Similar data were obtained in MDA-MB453 cells. Transient down-regulation of key members of the classical IKK- NF-κB pathway (p65, p52, c-Rel and NEMO) by siRNA in HeLa cells lead to a 30% increase in dox cytotoxicity. In contrast, silencing of RelB, a key subunit of the alternative pathway, had no effect on dox cytotoxicity under our assay conditions. Conclusions: NF-κB inhibition sensitized cells to dox, implying directly p65, p52, c-Rel and NEMO subunits in chemoresistance, but not RelB. These findings suggest that selective inhibition of the classical IKK-NF-κB pathway is sufficient to improve dox antitumor effects. [Table: see text]
Clinical effects of esophagectomy for patients 80 years of age and older with thoracic esophageal cancer
Authors: M. Morita, K. Nishida, T. Koga, A. Egashira, E. Tokunaga, E. Oki, N. Sadanaga, Y. Kakeji, Y. Maehara
Journal: Journal of Clinical Oncology (2006)

4049 Background: Esophageal cancer tends to mainly occur in elderly patients. Although a radical operation is the most effective existing therapy, the associated operative morbidity is still high. As a result, the indications for an esophagectomy in elderly patients (especially for patients over 80 years of age) remain controversial. Methods: A total of 599 patients with thoracic esophageal cancer who underwent an esophagectomy by the transthoracic approach since 1986 were evaluated. They were divided into 3 groups depending on age, namely groups I (&lt;69 y.o., n = 441), II (70–79 y.o., n = 143) and III (≥80 y.o., n = 15). No significant differences were observed in the location of the tumor, histological type or stage. A distal esophagectomy with a left thoracotomy was performed for 40, 46, and 47% of the patients, respectively, while the others underwent a subtotal esophagectomy with a right thoracotomy. In group III, surgery was only done for cases with PS 0 or 1 as well as a normal cardiac and pulmonary function (ejection fraction ≥65 %, vital capacity ≥80 %, FEV 1.0% &gt; 70%). Results: Postoperative complications occurred in 31 % of group I and 39 % of group II patients, and the incidence of pulmonary complication was 9 and 18 %, respectively (P &lt; 0.01). In group III, the operative morbidity and mortality were 27 and 0 %, respectively, and pulmonary complications only occurred in one patient (7%). No significant difference was observed in the disease-free survival (DFS: 50, 46 and 58 % for 3yrs, 44, 40 and 33 % for 5 yrs), while the overall survival rates were worse in the older groups as a result of death due to causes other than recurrence (45, 34 and 34 % for 3yrs and 38, 26 and 9 % for 5 yrs in groups I, II and III, respectively. P &lt; 0.01 group I v.s. II). Conclusions: An esophagectomy is considered to be a viable treatment alternative in patients over 80 years of age without increasing morbidity, when the indications for surgery are strictly determined. Furthermore, the DFS in these patients was similar to that observed in younger patients although the incidence of death due to causes other than cancer was found to be higher. An esophagectomy should therefore be considered as an effective treatment strategy even in elderly patients over 80 years of age. No significant financial relationships to disclose.
DETECTION OF STREPTOCOCCAL BACTERIAL DNA WITH POLYMERASE CHAIN REACTION IN EXCISED VALVULAR TISSUE OF RHEUMATIC HEART DISEASE PATIENTS
Authors: Nitin Parashar, Sivasubramanian Ramakrishnan, Sudheer Arava, Palleti Rajashekar, Mumun Sinha
Journal: Journal of the American College of Cardiology (2020)
THE IMPACT OF SOCIAL SUPPORT ON OUTCOMES AFTER LEFT VENTRICULAR ASSISTANCE DEVICE (LVAD) IMPLANTATION
Authors: Juliana Lawrence, Cesar Caraballo, Neal Ravindra, Paul Miller, Megan McCullough, Catherine Mezzacappa, Clancy Mullan, Fouad Chouairi, Nihar R. Desai, Tariq Ahmad
Journal: Journal of the American College of Cardiology (2020)
THE CLINICAL IMPACT OF PORTAL VEIN PULSATILITY ON THE PROGNOSIS OF HOSPITALIZED ACUTE HEART FAILURE PATIENTS
Authors: Naoya Kuwahara, Tomoyuki Honjo, Kenji Kaihotsu, Kouhei Kamemura, Kazuhiko Nakayama, Junichi Imanishi, Naohiko Sone, Masanori Iwahashi
Journal: Journal of the American College of Cardiology (2020)
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent nonresectable chondrosarcomas.
Authors: Ofer Merimsky, Rinat Bernstein-Molho, Yehuda Kollender
Journal: Journal of Clinical Oncology (2012)

10043 Background: Chondrosarcomas (CS) represent a heterogeneous group of rare sarcomas, poorly responsive to chemotherapy or radiotherapy. When local therapies in recurrent or metastatic disease are exhausted, chemotherapy plays a marginal role. Different molecular pathways have been shown to be activated in CS. In this retrospective study we summarize our experience in treating a cohort of patients with recurrent nonresectable CS with a combination of sirolimus and cyclophosphamide. Methods: Nine consecutive patients with nonresectable CS were offered off-label treatment with sirolimus and cyclophosphamide between 2007-2011. Tumor response, progression-free survival (PFS), adverse events and other relevant clinical data were analyzed. Results: The median patients’ age was 52 (range, 35-68). Median disease-free interval (DFI) since the primary diagnosis was 24 months. Median time from the disease recurrence to initiation of sirolimus and cyclophosphamide treatment was 20.9 months due to additional local surgical treatments/excision of metastases/slow and asymptomatic progression. One (11%) objective response was observed and five (56%) patients had stabilization of disease for at least 6 months. One patient has been treated for only 3.5 months and reported symptomatic improvement at this stage, two patients had progressive disease. Median time to treatment failure (TTF) was 15 months (range, 2.8-30.3). No significant adverse events were observed. Conclusions: Although advanced CS remains an incurable disease, our experience suggests that a combination of sirolimus and cyclophosphamide is well-tolerated and has meaningful clinical activity with clinical benefit rate of 67%. Further prospective studies are warranted.
Abstract 17214: Prediction of Mitral Valve Repair: Pre-Repair versus Virtual Repair versus Post-Repair
Authors: MyungGu Yeo, Tom T Nguyen, David D McPherson, Hyunggun Kim
Journal: Circulation (2018)

Introduction: Partial leaflet resection followed by ring annuloplasty is a reliable and reproducible mitral valve (MV) repair technique for the treatment of severe mitral regurgitation (MR) due to posterior chordal rupture. Hypothesis: We have developed a novel computational virtual MV repair strategy to predict the biomechanical and physiologic characteristics of post-repair MV dynamics to help with optimal surgical planning. Methods: Computational MV models were created using pre- and post-repair 3D echocardiographic data of a patient having posterior chordal rupture and severe MR. Virtual resection was designed by removing a pre-defined triangle-shaped leaflet portion in the P2 scallop and merging the excised leaflet edges. Virtual ring annuloplasty with the same ring size as the post-repair MV was performed following the triangular leaflet resection. Computational simulations of MV function (pre-repair, virtual repair, and post-repair) were performed using dynamic finite element methods. Leaflet coaptation across the MVs were quantitatively determined and compared. Results: The pre-repair MV with P2 chordal rupture showed severe P2 prolapse and leaflet malcoaptation. The post-repair MV demonstrated markedly reduced prolapse and sufficiently restored leaflet coaptation. The virtually repaired MV revealed a similar coaptation ratio as the post-repair MV indicating effective restoration of normal MV function. Both virtual repair and post-repair MVs showed improved coaptation not only in the P2 region but also in the A1-P1 and A3-P3 regions. Conclusions: We have quantitatively evaluated patient-specific MV function before and after potential MV repair using a novel virtual MV repair protocol. Both virtual repair and post-repair MVs decreased posterior leaflet prolapse and restored normal coaptation. This virtual MV repair strategy has the potential for improved pre-surgical planning to predict and optimize post-repair MV function.
LIVER FUNCTION AND PROGNOSIS, AND INFLUENCE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
Authors: Kota Suzuki, Brian Claggett, Masatoshi Minamisawa, Milton Packer, Michael Zile, Jean L. Rouleau, Karl Swedberg, Martin Lefkowitz, Victor Shi, John McMurray, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2020)